Preview

Вопросы современной педиатрии

Расширенный поиск

Ювенильная локализованная склеродермия с позиции детского ревматолога. Вопросы диагностики

https://doi.org/10.15690/vsp.v19i2.2109

Полный текст:

Аннотация

Локализованная склеродермия есть клинический вариант ювенильной склеродермии — третьего по частоте ревматического заболевания детского возраста. В статье обобщены знания о классификации, диагностике и дифференциальной диагностике ювенильной локализованной склеродермии. Освещены последние международные рекомендации по локализованной склеродермии у детей — Европейский консенсус детских ревматологов, немецкие и японские национальные рекомендации.

Об авторах

Р. К. Раупов
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

194100, Санкт-Петербург, ул. Литовская, д. 2.

тел.: +7 (812) 416-52-98



А. И. Имельбаев
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

194100, Санкт-Петербург, ул. Литовская, д. 2.

тел.: +7 (812) 416-52-98



М. М. Костик
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

Костик Михаил Михайлович - доктор медицинских наук, профессор кафедры госпитальной педиатрии СПбГПМУ.

194100, Санкт-Петербург, ул. Литовская, д. 2.

тел.: +7 (812) 416-52-98



Список литературы

1. Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017;31(4):576-595. doi: 10.1016/j.berh.2018.02.004.

2. Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62(2):213-218. doi: 10.1002/acr.20070.

3. Zulian F, Athreya BH, Laxer RM, et al. Juvenile Localized Scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5): 614-620. doi: 10.1093/rheumatology/kei251.

4. Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016;14(2):199-216. doi: 10.1111/ddg.12724.

5. Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011;(6):1308-1313. doi: 10.1111/j.1365-2133.2011.10600.x.

6. Hawley DP, Baildam EM, Amin TS, et al. Access to care for children and young people diagnosed with localized scleroderma or juvenile SSc in the UK. Rheumatology (Oxford). 2012;51(7): 1235-1239. doi: 10.1093/rheumatology/ker521.

7. Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018; 65(4):757-781. doi: 10.1016/j.pcl.2018.04.002.

8. Hawley DP, Pain CE, Baildam EM, et al. United Kingdom survey of current management of juvenile localized scleroderma. Rheumatology (Oxford). 2014;53(10):1849-1854. doi: 10.1093/rheumatology/keu212.

9. Локализованная склеродермия. Клинические рекомендации. — М.: Российское общество дерматовенерологов и косметологов, 2016. Доступно по: http://kokb45.ru/wp-content/uploads/2018/06/Lokalizovannaya-sklerodermiya. pdf. Ссылка активна на 12.02.2020.

10. Strickland, N, Patel, G, Strickland, A, Jacobe, H. Attitudes and trends in the treatment of morphea: a national survey. J Ame Acad Derm. 2015;72(4):727-728. doi: 10.1016/j.jaad.2014.11.019.

11. Asano Y, Fujimoto M, Ishikawa O, et al. Diagnostic criteria, severity classification and guidelines of localized scleroderma. J Dermatol. 2018;45(7):755-780. doi: 10.1111/1346-8138.14161.

12. Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78(8):1019-1024. doi: 10.1136/annrheum-dis-2018-214697.

13. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24(1):73-80.

14. Кубанова А.А., Кубанов А.А., Мелехина Л.Е., Богданова Е.В. Оценка состояния заболеваемости болезнями кожи и подкожной клетчатки в Российской Федерации за период 20032016 гг. // Вестник дерматологии и венерологии. — 2017. — № 6. — С. 22-33. doi: 10.25208/0042-4609-201793-6-22-33.

15. Khamaganova I. Localized scleroderma: predisposing and triggering factors. Open Derm J. 2017;11(1):1-11. doi: 10.2174/1874372201711010001.

16. Wolf R, Wolf D, Ruocco V, Ruocco Е. The role of skin trauma (isotopic and isomorphic) in the distribution of morphea. J Am Acad Dermatol. 2015;72(3):560-561. doi: 10.1016/j.jaad.2014.10.046.

17. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? a review. Br J Dermatol. 2000;142(4):636-644. doi: 10.1046/j.1365-2133.2000.03407.x.

18. Dillon WI, Saed GM, Fivenson DP. Borreliaburgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosusetatrophicus of patients from North America. J Am Acad Dermatol. 1995;33(4):617-620. doi: 10.1016/0190-9622(95)91281-9.

19. Weber K. Is juvenile localized scleroderma related to lyme Borreliosis? J Am Acad Dermatol. 2009;61(5):901. doi: 10.1016/j.jaad.2009.05.022.

20. Jacobe H, Ahn C, Arnett FC, Reveille JD. Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the morphea in adults and children cohort. Arthritis Rheumatol. 2014;66(11):3170-3177. doi: 10.1002/art.38814.

21. Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum. 2009;60(3):661-668. doi: 10.1002/art.24328.

22. Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of pediatric localized scleroderma. Front Immunol. 2019;10:908. doi: 10.3389/fimmu.2019.00908.

23. Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017;31(9):1401-1424. doi: 10.1111/jdv.14458.

24. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217-228. doi: 10.1016/j.jaad.2010.05.045.

25. Magee KE, Kelsey CE, Kurzinski KL, et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res Ther. 2013;15(6):R188. doi: 10.1186/ar4378.

26. Torok KS, Mi Q, Mirizio E, et al. Chemokine ligand 9 (CXCL9) [monokine induced by gamma interferon (MIG)] as a predictor of active disease status in localized scleroderma. Arthritis Rheumatol. 2017;69(Suppl 10):2346.

27. Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum. 2015;45(3):284-293. doi: 10.1016/j.semarthrit.2015.06.006.

28. Aractingi S, Socie G, Devergie A, et al. Localized sclerodermalike lesions on the legs in bone marrow transplant recipients: association with polyneuropathy in the same distribution. Br J Dermatol. 1993;129(2):201-203. doi: 10.1111/j.1365-2133.1993.tb03530.x.

29. McNallan KT, Aponte C, el-Azhary R, et al. Immunophenotyping of chimeric cells in localized scleroderma. Rheumatology (Oxford). 2007;46(3):398-402. doi: 10.1093/rheumatology/kel297.

30. Yi Ye, van Zyl B, Hemlata V, et al. Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis. Rheumatology (Oxford). 2012;51(6):987-991. doi: 10.1093/rheumatology/ker430.

31. Stevens AM, Hermes HM, Rutledge JC, et al. Myocardial-tissuespecific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet. 2003;362(9396):1617-1623. doi: 10.1016/S0140-6736(03)14795-2.

32. Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease? Arthritis Rheum. 1996;39(6):1041-1049. doi: 10.1002/art.1780390624.

33. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9): 2873-2881. doi: 10.1002/art.21264.

34. Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545-550. doi: 10.1001/archdermatol.2009.79.

35. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606-613. doi: 10.1097/01.bor.0000245727.40630.c3.

36. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068-1076 doi: 10.4065/70.11.1068.

37. Berianu F, Cohen MD, Abril A, Ginsburg WW. Eosinophilic fasciitis: clinical characteristics and response to methotrexate. Int J Rheum Dis. 2015;18(1):91-98. doi: 10.1111/1756-185X.12499.

38. Wu EY, Rabinovich EC, Torok KS, et al. Description of the localized scleroderma subgroup of the CARRAnet. Arthritis Rheumatol. 2011;63(Suppl 10):S787-88.

39. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. Br J Dermatol. 2008;159(1):175-181. doi: 10.1111/j.1365-2133.2008.08647.x.

40. Jablonska S, Blaszczyk M. Long-lasting follow-up favours a close relationship between progressive facial hemiatrophy and scleroderma en coup de sabre. J Eur Acad Dermatol Venereol. 2005; 19(4):403-404. doi: 10.1111/j.1468-3083.2005.00979.x.

41. Sommer A, Gambichler T, Bacharach-Buhles M, et al. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol. 2006;54: 227-233. doi: 10.1016/j.jaad.2005.10.020.

42. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257-263. doi: 10.1016/j.jaad.2006.10.959.

43. Wollina U, Buslau M, Weyers W, et al. Squamous cell carcinoma in panscleroticmorphea of childhood. Pediatr Dermatol. 2002; 19(2):151-154. doi: 10.1046/j.1525-1470.2002.00033.x.

44. Parodi PC, Riberti C, Draganic Stinco D, et al. Squamous cell carcinoma arising in a patient with long standing pansclerotic morphea. Br J Dermatol. 2001;144(2):417-419. doi: 10.1046/j.1365-2133.2001.04041.x.

45. Constantin T, Foeldvari I, Pain CE, et al. Development of minimum standards of care for juvenile localized scleroderma. Eur J Pediatr. 2018;177(7):961-977. doi: 10.1007/s00431-018-3144-8.

46. Li S, Torok K, Pope E, et al. Development of a clinical disease activity measure for juvenile localized scleroderma. Arthritis Rheum. 2011;63(Suppl 10):2453.

47. Weibel L, Sampaio MC, Visentin MT, et al. Evaluation of methotrexate and corticosteroidsfor the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5): 1013-1020. doi: 10.1111/j.1365-2133.2006.07497.x.

48. Kelsey CE, Torok KS. The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol. 2013;69(2):214-220. doi: 10.1016/j.jaad.2013.02.007.

49. Li SC, Andrews T, Chen M, et al. Extracutaneous involvement is common in juvenile localized scleroderma and associated with a higher level of perceived disease impact. Arthritis Rheumatol. 2017;69(suppl 10). Avlable from: https://acrabstracts.org/abstract/extracutaneous-involvement-is-common-in-juvenile-localized-scleroderma-and-associated-with-a-higher-level-of-per-ceived-disease-impact/.

50. Foster TD. The effects of hemifacial atrophy on dental growth. Br Dent J. 1979;146(5):148-150. doi: 10.1038/sj.bdj.4804213.

51. You KH, Baik HS. Orthopedic and orthodontic treatment of Parry-Romberg syndrome. J Craniofac Surg. 2011;22(3):970-973. doi: 10.1097/SCS.0b013e31820fe339.

52. Grippaudo C, Deli R, Grippaudo FR, et al. Management of craniofacial development in the Parry-Romberg syndrome: report of two patients. Cleft Palate Craniofac J. 2004;41(1):95-104. doi: 10.1597/02-066.

53. Trainito S, Favero L, Martini G, et al. Odontostomatologic involvement in juvenile localised scleroderma of the face. J Paediatr Child Health. 2012;48(7):572-576. doi: 10.1111/j.1440-1754.2012.02435.x.

54. Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol. 2007;91(10):1311-1314. doi: 10.1136/bjo.2007.116038.

55. Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric practice Res Group. Arch Pediatr Adolesc Med. 2000;154(2):150-154 doi: 10.1001/arch-pedi.154.2.150.

56. Hayashi M, Ichiki Y, Kitajima Y. Coexistence of recurrent generalized morphea and systemic sclerosis. Acta Derm Venereol. 2009;l89(3):329-330. doi: 10.2340/00015555-0645.

57. Carneiro S, Ramos-e-Silva M, Russi DC, et al. Coexistence of generalized morphea and lichen sclerosus et atrophicus mimicking systemic disease. Skinmed. 2011;9(2):131-133.

58. Wu EY, Li SC, Torok KS, et al. Baseline description of the juvenile localized scleroderma subgroup of the CARRA registry. ACR Open Rheumatol. 2019;1(2):119-124. doi: 10.1002/acr2.1019.

59. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford). 2005;44(3):274-279. doi: 10.1093/rheumatology/keh487.

60. Wortsman X, Wortsman J, Sazunic I, Carreno L. Activity assessment in morphea using color doppler ultrasound. J Am Acad Dermatol. 2011;65(5):942-948. doi: 10.1016/j.jaad.2010.08.027.

61. Li SC, Liebling MS, Haines KA. et al. Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2011;63(5):735-742. doi: 10.1002/acr.20407.

62. Serralta San MG, Lebrato J Canora. Clinical ultrasonography in systemic autoimmune diseases. Rev Clin Esp. 2019;S0014-2565(19)30223-30221. doi: 10.1016/j.rce.2019.07.014.

63. Horger M, Fierlbeck G, Kuemmerle-Deschner J, et al. MRI findings in deep and generalized morphea (Localized Scleroderma). Am J Roentgenol. 2008;190(1):32-39. doi: 10.2214/AJR.07.2163.

64. Schanz S, Fierlbeck G, Ulmer A, et al. Localized scleroderma: MR findings and clinical features. Radiology. 2011;260(3):817-824. doi: 10.1148/radiol.11102136.

65. Flores-Alvarado DE, Esquivel-Valerio JA, Garza-Elizondo M, Luis R Espinoza. Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? J Rheumatol. 2003;30(1):193-195.

66. Garcia-Romero MT, Randhawa HK, Laxer R, Pope E. The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. Int J Dermatol. 2017;56(1):63-67. doi: 10.1111/ijd.13452.

67. Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunological features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi: 10.1002/art.22207.

68. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford). 2007;46(5):856-860. doi: 10.1093/rheumatology/kel446.

69. McKee P, Calonje J, Granter S. Localized scleroderma. In: McKee P, Calonje E, Granter S. Pathology of the skin, with clinical correlations. 3rd ed. Philadelphia, PA: Mosby; 2005. Р. 815-821.

70. Sung JJ, Chen TS, Gilliam AC, et al. Clinicohistopathological correlations in juvenile localized scleroderma: studies on a subset of children with hypopigmented juvenile localized scleroderma due to loss of epidermal melanocytes. J Am Acad Dermatol. 2011;65(2):364-373. doi: 10.1016/j.jaad.2010.02.065.

71. Ingegnoli F, Boracchi P, Gualtierotti R, et al. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adultonset systemic sclerosis: a EUSTAR exploratory study. Microvasc Res. 2015;102:19-24. doi: 10.1016/j.mvr.2015.07.007.

72. Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis. 2003;62(5):444-449. doi: 10.1136/ard.62.5.444.

73. Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.

74. Mertens JS, Seyger MM, Kievit W, et al. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol. 2015;172(3): 722-728. doi:10.1111/bjd.13514.

75. Huyenlan D, Stephen MP, Chung C, Andrea LZ. Pediatric lichen sclerosus: a review of the literature and management recommendations. Clin Aesthet Dermatol. 2016;9(9):49-54.

76. Kirtschig G. Lichen sclerosus — presentation, diagnosis and management. Dtsch Arztebl Int. 2016;113(19):337-343. doi: 10.3238/arztebl.2016.0337.

77. Федеральные клинические рекомендации по ведению больных витилиго. — М.: Российское общество дерматовенерологов и косметологов, 2013. Доступно по: https://mz19.ru/upload/iblock/d1d/vit.pdf. Ссылка активна на 12.02.2020.

78. Moniuszko AM, Czupryna P, Dunaj J, et al. Acrodermatitis chronica atrophicans: various faces of a late form of Lyme borreliosis. Postepy Dermatol Alergol. 2018;35(5):490-494. doi: 10.5114/ada.2018.77240.

79. David P Arps, Rajiv M Patel. Lupus Profundus (panniculitis): a potential mimic of subcutaneous panniculitis-like T-Cell lymphoma. Arch Pathol Lab Med. 2013;137(9):1211-1215. doi: 10.5858/arpa.2013-0253-CR.


Для цитирования:


Раупов Р.К., Имельбаев А.И., Костик М.М. Ювенильная локализованная склеродермия с позиции детского ревматолога. Вопросы диагностики. Вопросы современной педиатрии. 2020;19(2):150-161. https://doi.org/10.15690/vsp.v19i2.2109

For citation:


Raupov R.K., Imelbaev A.I., Kostik M.M. Juvenile Localized Scleroderma from the Perspective of Pediatric Rheumatologist. Aspects of Diagnostics. Current Pediatrics. 2020;19(2):150-161. (In Russ.) https://doi.org/10.15690/vsp.v19i2.2109

Просмотров: 168


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)